Syngene International has entered a collaboration with Johns Hopkins University to support early-stage drug discovery programmes and platform technologies emerging from academic research laboratories.

The partnership will focus on advancing preclinical assets through Syngene’s SynVent platform, which integrates discovery biology, medicinal and synthetic chemistry, drug metabolism and pharmacokinetics, toxicology and early development capabilities. The companies said the collaboration is designed to help translate university-based research into development-ready therapeutic candidates.

Under the agreement, Syngene will also apply its Connector model, which brings together academic innovators, biopharma companies and investors to support promising early-stage programmes. The aim is to secure research sponsorship and potential licensing pathways for intellectual property generated through the collaboration.

Kenneth Barr, senior vice president and head of strategic collaborations at Syngene International, said: “We are delighted to be working with a renowned institution like Johns Hopkins. We are uniquely positioned to translate pioneering research into credible therapeutic candidates, and our goal is to significantly compress the time required for high-potential programs to become clinically relevant, creating a faster and more efficient pipeline of new medicines.”

The collaboration reflects a broader trend of contract research, development and manufacturing organisations expanding their role beyond fee-for-service research into strategic early-stage partnerships with academic institutions. By integrating drug discovery capabilities with external funding and licensing networks, CRDMOs are increasingly positioning themselves as translational partners in the drug development pathway.

Paul Nkansah, senior director of corporate partnerships at Johns Hopkins Technology Ventures, said the model could help bridge the gap between laboratory discoveries and commercial development.

He added that the collaboration has “the potential to link discoveries from Johns Hopkins laboratories with the drug discovery capabilities of Syngene, pharmaceutical and biotech partners, and investors – accelerating groundbreaking innovations developed at Johns Hopkins and turning promising science into credible development programs that could ultimately lead to new options for patients.”

Johns Hopkins University is a major US research institution with a strong track record in biomedical innovation, while India-based Syngene has expanded its global footprint in recent years through growth in integrated discovery and development services. The companies did not disclose financial terms of the agreement.

While no specific therapeutic areas were outlined, the collaboration is expected to focus on early-stage drug discovery programmes with clear translational potential. The structure suggests a focus on de-risking academic science before it enters formal clinical development pathways.

The agreement underscores continued investment in academic–industry partnerships as drug developers seek access to novel targets, platform technologies and first-in-class science originating in university research environments.